Genentech buys Regor’s CDK inhibitors in $850m deal
Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including ...
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
emjreviews.com8h
Genentech acquires Regor’s next-gen CDK inhibitor portfolio
Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth ...
Pharmabiz18h
Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer
Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer: Cambridge, Massachusetts Tuesday, October 1, 2024, 10:00 Hrs [IST] Regor Pharmaceutica ...